BRCA1 and neoplasm: On Cox regression analysis, longer OS was associated with increased duration of platinum-based therapy (HR 0.98, 95% CI 0.95–0.99, p = 0.04), while adjusting for tumor site, HRD and SBS3 scores, and BRCA1/2 mutation status.